CD19
Showing 26 - 50 of 8,705
Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)
Completed
- Acute Lymphoblastic Leukemia
- CAR-NK-CD19 Cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Nov 24, 2022
B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)
Recruiting
- B-Cell Leukemia
- +2 more
- Anti-CD19 Autologous CAR-T Cell Infusion
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Relapsed and Refractory B-cell Lymphoma Trial (CD19 CAR-T and CD19 CAR-DC)
Not yet recruiting
- Relapsed and Refractory B-cell Lymphoma
- CD19 CAR-T and CD19 CAR-DC
- (no location specified)
Oct 16, 2022
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non Hodgkin's Lymphoma
- Allogenic CD19-CAR-γδT cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Jan 31, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)
Not yet recruiting
- SLE (Systemic Lupus)
- CAR T-cell therapy
-
Bangkok, Please Select, ThailandKing Chulalongkorn Memorial Hospital
Nov 23, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- UCAR-T Cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022
Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- allogenic CD19-CAR-NK cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023
B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)
Recruiting
- B-cell Non Hodgkin Lymphoma
- regimen with BTK inhibitor +Anti-CD19 CAR T cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia Trial (CliniMACS® device)
Not yet recruiting
- Graft Vs Host Disease
- +5 more
- CliniMACS® device
- (no location specified)
Jul 20, 2023
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)
Recruiting
- B-cell Non-Hodgkin's Lymphoma
- Human CD19Targeted T Cells Injection
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Jun 29, 2022
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Human CD19 Targeted DASH CAR-T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)
Recruiting
- Diffuse Large B-cell Lymphoma
- CD19-7×19 CAR-T combined with Tislelizumab
-
Hangzhou, Zhejiang, China
- +1 more
Dec 12, 2022
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- CD19-CAR(Mem) T-cells
- +5 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 5, 2022
B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)
Active, not recruiting
- B-cell Lymphoma
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022
Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- anti-CD19 CAR NK cells
- (no location specified)
Dec 21, 2022